Eli Lilly and Company (LLY)
3 Companies Gearing Up for a Stock Split
Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.
Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs. Approval of tirzepatide for weight management in China and the EU opens up new markets for the company. Despite strong growth potential, Eli Lilly's stock remains pricey, with upcoming earnings report potentially changing the investment outlook.
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Eli Lilly has some exciting opportunities in weight loss in the future, but investors shouldn't overlook its impressive dividend. Broadcom's business is booming due to artificial intelligence, and that can lead to more rate hikes to its dividend.
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.
Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China
Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly's weight loss drug tirzepatide gets approval in China
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly's ( NYSE: LLY ) stock price chart has been straight up and to the right, up 553% and currently trading at $848.74.
Eli Lilly's stock plunges as investors eye obesity-drug competition
Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.
